MEDDEV ADVISORY

SAMPLE PREVIEW

Material Change Biocompatibility Impact Assessment Pack

Final-finished device material, supplier, process, sterilization, packaging, ageing, and configuration change controls

A candid pre-purchase view of the files, controls, fictional workflow, and professional-judgment boundary

MDA-TLK-CHANGE-BIO-10993-01 • v3.0 • PUBLIC PRODUCT PREVIEW

PRE-PURCHASE TOUR — COMPLETE PAID FILES NOT INCLUDED

Help medical-device teams decompose a proposed change, freeze the current and candidate final-finished configurations, identify affected biological questions, appraise prior evidence, and prepare traceable records for qualified scientific and jurisdiction-specific review.

A structured working aid. It does not determine biological safety, compliance, or regulatory acceptance.

What this resource helps a team produce

- A bounded change charter that separates one business request into independently reviewable change units and records cumulative interactions.
- A current-versus-candidate final-finished-device baseline covering components, formulations, suppliers, sites, processes, residues, sterilization, packaging, ageing, and use.
- A component-level contact and exposure delta map that shows what can change even when nominal material or intended use appears unchanged.
- Question-specific material, supplier, process, cleaning, residue, sterilization, packaging, ageing, and configuration evidence records.
- A difference-by-difference bridge from every cited report or prior device to the candidate configuration, with limitations and open actions preserved.
- A chemistry and toxicological-assessment trigger record that distinguishes an evidence need from an automatic test or acceptance decision.
- A fail-closed biological-impact synthesis that cannot show a completed control while required scope, evidence, rationale, decision, reviewer, date, or action closure is missing.
- Source-dated FDA, EU MDR, and CDSCO working maps that keep quality-system change control separate from regulatory reporting or submission decisions.

SCOPE This resource structures biological-impact evidence and change-review preparation. It does not decide test selection, establish material or biological equivalence, determine toxicological acceptability or biological safety, authorize implementation, select a regulatory reporting route, demonstrate conformity, constitute a submission, or predict regulator acceptance. Device-specific decisions require qualified biological-safety, toxicology, materials, sterilization or packaging, risk-management, and jurisdiction-specific regulatory review as applicable.

The working sequence

Step	Action	Output
1	Freeze one controlled candidate, intended implementation date, affected markets, current device, candidate device, and exact decision request.	Change assessment charter
2	Split the request into atomic material, supplier, site, process, cleaning, sterilization, packaging, ageing, coating, additive, geometry, and configuration change units.	Change decomposition and interaction map
3	Freeze both final-finished configurations and map component-level contact, exposure, use, population, and cumulative-contact deltas.	Baseline and exposure delta file
4	Collect controlled supplier, formulation, process, residue, sterilization, packaging, ageing, and prior-evidence records with exact locators.	Change evidence register
5	Compare each evidence article and prior configuration to the candidate, one relevant attribute at a time, including cumulative changes.	Representativeness bridge
6	Record chemistry, toxicology, endpoint, risk, PMS, and specialist triggers without automatically selecting a test or conclusion.	Biological-impact synthesis
7	Route FDA, EU, CDSCO, PMA, 510(k), legacy-device, correction or removal, and quality-system questions to the correct current source and reviewer.	Jurisdictional route index
8	Reverify sources, reconcile all files, close or formally block actions, remove fictional records, and submit the exact candidate for independent qualified review.	Controlled review candidate



Decision dashboard

Fail-closed status view — this is not a compliance or safety score | v3.0-rc1

CONTROL COUNTS

Assessment items	24
Incomplete controls	38
Critical items	0
Missing evidence	0
Weak evidence	0
Open red flags	0
Open actions	1

OVERALL CONTROL STATUS

ASSESSMENT INCOMPLETE

INTERPRETATION

The dashboard enforces sequencing and escalation. It does not decide endpoint applicability, evidence adequacy, test selection, toxicological acceptability, biological safety, conformity, or regulator acceptance. Resolve each row and preserve the supporting evidence and named reviewer decision.

Decision dashboard - strict workflow completeness and escalation view from the current candidate build



Biological-impact synthesis

Fail-closed control record for scope, evidence, science, lifecycle, jurisdiction, and review | v3.0-rc1

Complete every seeded row. Invalid text, open/blocked actions, unfinished review, missing companions, or unsupported not-applicable choices cannot complete a control.

Control ID	Control / biological question	Applicability	Evidence stat	Evidence IDs / findings	Rationale / contrary data / limitations	Decision / action ID	Reviewer / competence	Decision date / trigger	Control check
BIA-001	Controlled current device, candidate, change request, market scope, decision request, and explicit exclusions	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-002	Atomic change units, cumulative history, interactions, implementation states, and affected configurations	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-003	Current and candidate component, drawing, formulation, supplier, manufacturer, site, and assembly baselines	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-004	Manufacturing, joining, coating, printing, lubrication, cleaning, rinse, drying, rework, and residue baselines	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-005	Sterilization, aeration, packaging, transport, ageing, shelf life, storage, and preparation-to-use baselines	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-006	Component-level direct and indirect contact, tissue/fluid, duration, frequency, population, and use conditions	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-007	Exposure drivers, affected variants, question-specific representative conditions, and cumulative exposure	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-008	Material, formulation, additive, impurity, processing-aid, supplier, site, and variability evidence	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-009	Manufacturing, cleaning, residue, surface, physical-state, and particulate change evidence	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-010	Sterilization modality, cycle, material compatibility, residual, load, package, and ageing interaction evidence	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-011	Packaging materials, inks, adhesives, sealing, transport, migration, abrasion, and shelf-life evidence	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-012	Complete evidence identity, method, article, findings, deviations, adverse information, quality, and locators	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-013	Difference-by-difference and cumulative representativeness bridge from every cited article to the candidate	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-014	Chemical-characterization trigger, analytical coverage, final-device article, unknowns, and uncertainty	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-015	Toxicological-assessment trigger, exposure basis, population, source quality, uncertainty, and conclusion scope	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-016	Endpoint-specific biological questions and evidence routes appropriate to contact, duration, device, and change	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-017	Physical interaction, degradation, wear, particle, coating, surface, or local-response questions as applicable	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-018	Risk-management, clinical, complaint, vigilance, CAPA, PMS, PMCF, and contrary-signal linkage	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-019	Supplier/site qualification, implementation prerequisites, lot segregation, traceability, monitoring, and rollback	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-020	FDA device status, 510(k)/PMA/other route, QMSR, correction/removal relevance, and approved decision	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-021	EU MDR or Article 120 legacy-device status, technical-documentation impacts, standards status, and approved decision	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-022	CDSCO licence, class, current rules/notices, post-approval change evidence, and approved decision	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-023	Official sources, controlled standards, edition, recognition, harmonization, draft/final, and transition status	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN
BIA-024	Qualified scientific, specialist, jurisdiction-specific, independent, implementation, and exact-candidate release review	Conditional—decide	Not assessed						INCOMPLETE — OPEN ACTIONS REMAIN

Biological-impact synthesis - seeded scope, evidence, scientific, lifecycle, jurisdiction, source, and approval controls

WHAT THE PREVIEW DEMONSTRATES The product controls change scope, final-device deltas, exposure, evidence, scientific triggers, lifecycle inputs, jurisdictional routes, actions, and qualified decisions. It does not supply a prewritten equivalence, no-impact, safety, testing, filing, or implementation conclusion.

Exactly what is included

File	Use it for	Complete when
Quick Start PDF	Set the candidate boundary, follow the safe sequence, and recognize the stop conditions before entering conclusions.	The team knows the exact current and candidate devices, change units, owners, source date, review sequence, and implementation hold.
Implementation Guide PDF	Understand final-device baselines, change mechanisms, evidence bridges, scientific triggers, lifecycle links, and jurisdictional boundaries.	The team can explain each proposed conclusion, limitation, action, and reserved approval without using unsupported equivalence or no-impact language.
Editable Working Templates DOCX	Draft the charter, baselines, decomposition, exposure map, evidence bridge, trigger memos, route index, and release decisions.	Every response area is device specific and every uncertainty has an owner, action, due date, and decision path.
Operational Workbook XLSX	Control facts, evidence, source status, biological-impact states, red flags, actions, and decisions.	No invalid or incomplete control remains, open/blocked actions are resolved, and terminal rows contain evidence, rationale, decision, reviewer, date, and trigger.
Source Status and Release Notes PDF	Verify current ISO publication, FDA recognition, EU harmonisation, legal, guidance, transition, and draft/final status.	The register matches the exact authorities and controlled source editions used for the candidate decision.
Customer README, responsible-use terms, and source register	Orient recipients, preserve identity, and control authorized use and update expectations.	Title, product and workbook IDs, version, files, source date, support route, and use boundaries agree.

What is deliberately not promised

- No automated test selection, endpoint applicability, worst case, material equivalence, biological-safety, toxicological-acceptability, or no-new-test decision.
- No automated 510(k), PMA, QMSR, corrections/removals, EU MDR, Article 120 legacy-device, CDSCO, notified-body, filing, notification, or implementation route.
- No conformity, submission-readiness, approval, or regulator-acceptance determination.
- No universal coverage of software-only, labeling-only, clinical-investigation, combination, tissue-derived, IVD, custom, patient-matched, degradable, resorbable, nanomaterial, or other specialist device changes.
- No reproduction of ISO standards or replacement for lawfully obtained standards, current legal text, device-specific guidance, certificate/licence conditions, and qualified review.
- No guarantee that prior evidence remains applicable after a material, formulation, supplier, site, process, residue, sterilization, packaging, ageing, shelf-life, use, population, or configuration change.

AVAILABILITY Current customer edition — available by request. Online checkout, payment collection, public buyer-file download, and automatic delivery are not enabled.